Otte A - Search Results

1

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.

Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, Freitag P, Reubi JC, Müller-Brand J, Gratzl O, Mäcke HR. Merlo A, et al. Among authors: otte a. Clin Cancer Res. 1999 May;5(5):1025-33. Clin Cancer Res. 1999. PMID: 10353735 Clinical Trial.

2

[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].

Otte A, Herrmann R, Mäcke HR, Müller-Brand J. Otte A, et al. Praxis (Bern 1994). 1999 Aug 15;88(31-32):1263-8. Praxis (Bern 1994). 1999. PMID: 10479965 German.

3

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.

Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. Otte A, et al. Eur J Nucl Med. 1997 Jul;24(7):792-5. doi: 10.1007/BF00879669. Eur J Nucl Med. 1997. PMID: 9211767

4

Yttrium-90 DOTATOC: first clinical results.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J. Otte A, et al. Eur J Nucl Med. 1999 Nov;26(11):1439-47. Eur J Nucl Med. 1999. PMID: 10552085

5

[Cortical blindness following heroin intoxication].

Brändli M, Otte A, Müller-Brand J. Brändli M, et al. Among authors: otte a. Nuklearmedizin. 2000;39(2):N16-9. Nuklearmedizin. 2000. PMID: 10768171 German. No abstract available.

6

Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [18F]fluorodeoxyglucose and [11C]methionine.

Otte A, Roelcke U, von Ammon K, Hausmann O, Maguire RP, Missimer J, Müller-Brand J, Radü EW, Leenders KL. Otte A, et al. J Neurol Sci. 1998;156(1):73-7. doi: 10.1016/s0022-510x(98)00019-7. J Neurol Sci. 1998. PMID: 9559990

7

Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.

Görres G, Kaim A, Otte A, Götze M, Müller-Brand J. Görres G, et al. Among authors: otte a. Eur J Nucl Med. 1996 Jun;23(6):690-2. doi: 10.1007/BF00834532. Eur J Nucl Med. 1996. PMID: 8662104

8

[Marine-Lenhart syndrome: a case observation upon 18 years].

Waldherr C, Otte A, Haldemann A, Müller-Brand J. Waldherr C, et al. Among authors: otte a. Nuklearmedizin. 1999;38(8):345-8. Nuklearmedizin. 1999. PMID: 10615671 German.

9

[Influence of hormone substitution therapy on postmenopausal uterus].

Otte A, Rüdisüli A, Goetze M, Leibundgut U, Nitzsche EU, Müller-Brand J. Otte A, et al. Nuklearmedizin. 1997 Dec;36(8):295-7. Nuklearmedizin. 1997. PMID: 17068882 German.

10

End-stage renal disease after treatment with 90Y-DOTATOC.

Cybulla M, Weiner SM, Otte A. Cybulla M, et al. Among authors: otte a. Eur J Nucl Med. 2001 Oct;28(10):1552-4. doi: 10.1007/s002590100599. Eur J Nucl Med. 2001. PMID: 11685499

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

354 results

Search Page

Filters